Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
5.14
+0.16 (3.21%)
Dec 20, 2024, 4:00 PM EST - Market closed
Foghorn Therapeutics Revenue
Foghorn Therapeutics had revenue of $7.81M in the quarter ending September 30, 2024, a decrease of -55.33%. This brings the company's revenue in the last twelve months to $25.52M, down -21.66% year-over-year. In the year 2023, Foghorn Therapeutics had annual revenue of $34.16M with 77.63% growth.
Revenue (ttm)
$25.52M
Revenue Growth
-21.66%
P/S Ratio
10.02
Revenue / Employee
$219,957
Employees
116
Market Cap
285.75M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accolade | 441.03M |
Procaps Group | 414.10M |
Canopy Growth | 207.63M |
Cerus | 176.23M |
C4 Therapeutics | 33.67M |
Aclaris Therapeutics | 27.08M |
aTyr Pharma | 235.00K |
4D Molecular Therapeutics | 17.00K |
FHTX News
- 5 days ago - Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - GlobeNewsWire
- 5 weeks ago - Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewsWire
- 3 months ago - Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update - GlobeNewsWire